Holen Sie sich die Stockscreener-App
1.14
2.70%
0.03
Handel nachbörslich:
1.11
-0.03
-2.63%
Sunshine Biopharma Inc Aktie (SBFM) Neueste Nachrichten
Sunshine Biopharma receives Canadian approval for atenolol tablets By Investing.com - Investing.com Nigeria
Sunshine Biopharma Announces Board Vacancy as Dr. Andrew Keller Steps Down After Term Ends - Kalkine Media
SBFM Looks 52.9% Undervalued on GF Value™ Despite Weak Fundamentals - GuruFocus
Health Canada approves Atenolol, a drug used for high blood pressure and chest pain - Stock Titan
Sunshine Biopharma (NASDAQ: SBFM) could raise $31M from warrants - Stock Titan
Dr. Andrew Keller to Leave Sunshine Biopharma Board at Term End - tradingview.com
Sunshine Biopharma Inc. Announces Term Completion of Dr. Andrew Keller as Director - marketscreener.com
Sunshine Biopharma Inc. (SBFM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Sunshine Biopharma Inc. (SBFM) Key Financial Ratios – Valuation, Profitability & More - Value Research
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer - guardonline.com
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer - Benzinga
Sunshine Biopharma Inc. Warrant (SBFMW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Sunshine (SBFMW) Market: Closes Nearly Flat at $0.05 in the Available Record; Levels: the Current Price Sits Inside the Supplied Technical RangeExhaustion Gap - vinanet.vn
Sunshine Biopharma wins Canadian approval for generic Enalapril tablets - Bitget
SBFM Looks 55.2% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
BRIEF-Sunshine Biopharma Receives Canadian Regulatory Approval For Enalapril - Bitget
Sunshine Biopharma receives Canadian approval for generic enalapril By Investing.com - Investing.com Canada
Sunshine Biopharma receives Canadian approval for generic enalapril - Investing.com
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market - Eagle-Tribune
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug - Yahoo Finance
Sunshine (SBFM) Quarterly Performance Check: The Company Lists Its Latest Available Figures in the Reported Period; Session Reaction: The Stock Ends Up 1.79% in the Latest ReadingEarnings Momentum Score - vinanet.vn
101,973 Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-AUG-2026. - marketscreener.com
Sunshine Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
SBFM Q1 2026 Earnings: Clinical-Stage Biotech Posts $0.25 Per-Share Loss as Shares Slip 4.17%Revenue Warning Signal - vinanet.vn
SBFM Q1 2026 Earnings: Reported Loss of $0.25 Per Share as Stock Declines 4.17%Pre-Earnings Setup - Vinanet
Sunshine Biopharma Inc (NASDAQ: SBFM) Share Price, SBFM Stock News, SBFM Share Price & Updates - kalkine.ca
SBFM Q1 2026 Earnings: Net Loss of -$0.25 Per Share as Pre-Revenue Oncology Developer Presses OnForward Guidance Trends - vinanet.vn
L1 Capital (SBFM) discloses 4.99% Sunshine Biopharma stake plus large warrant position - Stock Titan
Sunshine Biopharma (SBFM) investors cap warrant-driven stake at 9.99% - Stock Titan
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market - The Lawton Constitution
Sunshine Biopharma (SBFM) Holds Gains at $1.23 as Stock Stays Rangebound Between Key LevelsActive ETF Flow - dars.gov.et
SBFM Q1 2026 Earnings: Net Loss of $0.25 Per Share Highlights Pre-Commercial Biotech StageGuidance Downgrade Alert - vinanet.vn
SBFM Stock Holds Support As Traders Eye Next Move - timothysykes.com
SBFM Stock Holds Support As Sunshine Biopharma Tightens Cash Control - StocksToTrade
SBFM Stock Holds Range As Traders Weigh Weak Margins - timothysykes.com
SBFM Stock Slides As Traders Focus On Cash Runway And Volatility - StocksToTrade
SBFM Stock Pops As Health Canada Greenlights New Generics - StocksToTrade
Amoxicillin Market Estimated at $4.9B as Canada Shipments Begin - Stock Titan
Sunshine Biopharma Inc. Revenue Breakdown – NASDAQ:SBFMW - TradingView
SBFM Looks 84.2% Undervalued on GF Value™ Despite Distressed Fun - GuruFocus
Sunshine Biopharma receives Canadian approval for generic dienogest By Investing.com - Investing.com Nigeria
Sunshine Biopharma receives Canadian approval for generic dienogest - Investing.com
Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval - Stock Titan
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval - Benzinga
SBFM Q2'26 Earnings: EPS estimate is (1.20) USD - TradingView
Sunshine Biopharma wins Canadian approval for generic Dienogest tablets - Bitget
Sunshine Biopharma cuts exercise price of outstanding Series B warrants to $1.22 - Bitget
Sunshine Biopharma Inc. (SBFM) Q1 2026 Earnings: Widening Losses as Pre‑Revenue Biotech Navigates Pipeline MilestonesNet Profit Margin - dars.gov.et
SBFM Looks 79.1% Undervalued on GF Value™ Amid Challenging Finan - GuruFocus
Sunshine Biopharma receives Canadian approval for ondansetron - Investing.com
Sunshine Biopharma receives Canadian approval for ondansetron By Investing.com - Investing.com Canada
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting - New Castle News
Sunshine Biopharma Inc (SBFM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SBFM|Sunshine Biopharma Inc|Price:1.696| - TradingKey
Sunshine Biopharma Inc (SBFM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SBFM|Sunshine Biopharma Inc|Price:1.230|Chg%:-0.170 - TradingKey
SBFM|Sunshine Biopharma Inc|Price:1.145|Chg%:-0.055 - TradingKey
Sunshine Biopharma Inc (SBFM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SBFM Q1 2026 Earnings: Net Loss Widens as Pre-Revenue Biotech Focuses on R&D Pipeline - vinanet.vn
Sunshine Biopharma Inc. (SBFM) Q1 2026 Earnings: Continued R&D Investment Drives Net Loss, No Revenue ReportedEarnings Outlook Update - dars.gov.et
Sunshine Biopharma Inc. Revenue Breakdown – NASDAQ:SBFM - tradingview.com
Sunshine Biopharma Inc. Revenue Breakdown – BOATS:SBFMW - TradingView
1.66%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):